The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis

References

• Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387(6630):296-9; PMID:9153395; https://doi.org/10.1038/387296a0
   PubMed Web of Science ®Google Scholar
• Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387(6630):299-303; PMID:9153396; https://doi.org/10.1038/387299a0
   PubMed Web of Science ®Google Scholar
• Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009; 137(3):413-31; PMID:19410540; https://doi.org/10.1016/j.cell.2009.04.037
   PubMed Web of Science ®Google Scholar
• Laptenko O, Prives C. Transcriptional regulation by p53: One protein, many possibilities. Cell Death Differ 2006; 13(6):951-61; PMID:16575405; https://doi.org/10.1038/sj.cdd.4401916
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-moleculeantagonists of MDM2. Science 2004; 303(5659):844-8; PMID:14704432; https://doi.org/10.1126/science.1092472
   PubMed Web of Science ®Google Scholar
• Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, et al. MDM2 small-molecule antagonist RG7112 activates p53signaling and regresses human tumors in preclinical cancer models. Cancer Res 2013; 73(8):2587-97; PMID:23400593; https://doi.org/10.1158/0008-5472.CAN-12-2807
   PubMed Web of Science ®Google Scholar
• Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signalingin cancer: Implications for therapy. Proc Natl Acad Sci U S A 2006; 103(6):1888-93; PMID:16443686; https://doi.org/10.1073/pnas.0507493103
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S. Activation of p53 by Nutlin-3a, an antagonist of MDM2, inducesapoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia 2009; 23(11):2090-101; PMID:19710698; https://doi.org/10.1038/leu.2009.171
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a criticaldeterminant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 2008; 27(40):5303-14; PMID:18521084; https://doi.org/10.1038/onc.2008.164
   PubMed Web of Science ®Google Scholar
• Shen H, Maki CG. Persistent p21 expression after Nutlin-3a removal is associated with senescence-likearrest in 4N cells. J Biol Chem 2010; 285(30):23105-14; PMID:20489208; https://doi.org/10.1074/jbc.M110.124990
   PubMed Web of Science ®Google Scholar
• Shen H, Moran DM, Maki CG. Transient nutlin-3a treatment promotes endoreduplication and thegeneration of therapy-resistant tetraploid cells. Cancer Res 2008; 68(20):8260-8; PMID:18922897; https://doi.org/10.1158/0008-5472.CAN-08-1901
   PubMed Web of Science ®Google Scholar
• Huang B, Deo D, Xia M, Vassilev LT. Pharmacologic p53 activation blocks cell cycle progression butfails to induce senescence in epithelial cancer cells. Mol Cancer Res 2009; 7(9):1497-509; PMID:19737973; https://doi.org/10.1158/1541-7786.MCR-09-0144
   PubMed Web of Science ®Google Scholar
• Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, et al. Insulin-like growth factor (IGF) signaling in tumorigenesis andthe development of cancer drug resistance. Genes Dis 2015; 2(1):13-25; PMID:25984556; https://doi.org/10.1016/j.gendis.2014.10.004
   PubMed Web of Science ®Google Scholar
• Abedini MR, Muller EJ, Bergeron R, Gray DA, Tsang BK. Akt promotes chemoresistance in humanovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-likeinhibitory protein. Oncogene 2009; 29(1):11-25; PMID:19802016; https://doi.org/10.1038/onc.2009.300
   PubMed Web of Science ®Google Scholar
• Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA. PKB and the mitochondria: AKTing onapoptosis. Cell Signal 2008; 20(1):21-30; PMID:17716864; https://doi.org/10.1016/j.cellsig.2007.07.010
   PubMed Web of Science ®Google Scholar
• Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011; 1813(11):1978-86; PMID:21440011; https://doi.org/10.1016/j.bbamcr.2011.03.010
   PubMed Web of Science ®Google Scholar
• Pene F, Claessens YE, Muller O, Viguié F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21(43):6587-97; PMID:12242656; https://doi.org/10.1038/sj.onc.1205923
   PubMed Web of Science ®Google Scholar
• Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Grigsby PW, Schwarz JK. AKT inhibitors promote cell death in cervical cancer throughdisruption of mTOR signaling and glucose uptake. PloS One 2014; 9(4):e92948; PMID:24705275; https://doi.org/10.1371/journal.pone.0092948
   PubMed Web of Science ®Google Scholar
• Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through directphosphorylation of Ulk1. Nat Cell Biol 2011; 13(2):132-41; PMID:21258367; https://doi.org/10.1038/ncb2152
   PubMed Web of Science ®Google Scholar
• Zhu N, Gu L, Li F, Zhou M. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect ofnutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther 2008; 7(5):1101-9; PMID:18483299; https://doi.org/10.1158/1535-7163.MCT-08-0179
   PubMed Web of Science ®Google Scholar
• Saiki AY, Caenepeel S, Yu D, Lofgren JA, Osgood T, Robertson R, Canon J, Su C, Jones A, Zhao X, et al. MDM2 antagonists synergize broadly and robustly with compoundstargeting fundamental oncogenic signaling pathways. Oncotarget 2014; 5(8):2030-43; PMID:24810962; https://doi.org/10.18632/oncotarget.1918
   PubMed Web of Science ®Google Scholar
• Xiong L, Kou F, Yang Y, Wu J. A novel role for IGF-1R in p53-mediated apoptosis through translationalmodulation of the p53-Mdm2 feedback loop. J Cell Biol 2007; 178(6):995-1007; PMID:17846171; https://doi.org/10.1083/jcb.200703044
   PubMed Web of Science ®Google Scholar
• Davaadelger B, Duan L, Perez RE, Gitelis S, Maki CG. Crosstalk between the IGF-1R/AKT/mTORC1pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits theeffectiveness of an IGF-1R pathway inhibitor. Oncotarget 2016; 7(19):27511-26; PMID:27050276; https://doi.org/10.18632/oncotarget.8484
   PubMed Web of Science ®Google Scholar
• Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB andDNA-PK. Proc Natl Acad Sci (USA) 2008; 105(22):7785-90; PMID:18505846; https://doi.org/10.1073/pnas.0703423105
   PubMed Web of Science ®Google Scholar
• Vadysirisack DD, Baenke F, Ory B, Lei K, Ellisen LW. Feedback control of p53 translation by REDD1and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol 2011; 31(21):4356-65; PMID:21896779; https://doi.org/10.1128/MCB.05541-11
   PubMed Web of Science ®Google Scholar
• Duan L, Perez RE, Davaadelger B, Dedkova EN, Blatter LA, Maki CG. p53-regulated autophagy iscontrolled by glycolysis and determines cell fate. Oncotarget 2015; 6(27):23135-56; PMID:26337205; https://doi.org/10.18632/oncotarget.5218
   PubMed Web of Science ®Google Scholar
• Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res 2009; 152:15-32; PMID:20213384; https://doi.org/10.1007/978-1-4419-0284-9_2
   PubMedGoogle Scholar
• O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009; 9(4):511-23; PMID:18505846; https://doi.org/10.1586/era.09.7
   PubMed Web of Science ®Google Scholar
• Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, et al. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23(3):559-68; PMID:15659502; https://doi.org/10.1200/JCO.2005.04.063
   PubMed Web of Science ®Google Scholar
• O'Reilly KE, Rojo, F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling andactivates AKT. Cancer Res 2006; 66(3)1500-8; PMID:16452206; https://doi.org/10.1158/0008-5472.CAN-05-2925
   PubMed Web of Science ®Google Scholar
• Russell RC, Yuan H-X, Guan K-L. Autophagy regulation by nutrient sensing. Cell Res 2014; 24:42-57; PMID:24343578; https://doi.org/10.1038/cr.2013.166
   PubMed Web of Science ®Google Scholar
• Kim YC, Guan K-L. mTOR: A pharmacologic target for autophagy regulation. J Clin Invest 2015; 125(1) 25-32; PMID:25654547; https://doi.org/10.1172/JCI73939
   PubMed Web of Science ®Google Scholar
• Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulatetranscription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A 1996; 93:8318-23; PMID:8710868; https://doi.org/10.1073/pnas.93.16.8318
   PubMed Web of Science ®Google Scholar
• Goetz EM, Shankar B, Zou Y, Morales JC, Luo X, Araki S, Bachoo R, Mayo LD, Boothman DA. ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in geneticinstability. Oncogene 2011; 30:3745-54; PMID:21460853; https://doi.org/10.1038/onc.2011.92
   PubMed Web of Science ®Google Scholar
• Ryan KM, Vousden KH. p53 and metabolism. Nat Rev Cancer 2009; 9:691-700; PMID:19759539; https://doi.org/10.1038/nrc2715
   PubMed Web of Science ®Google Scholar
• Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for properactivation of mTOR complex 2. Mol Cell Biol 2008; 28(12) 4104-15; PMID:18411301; https://doi.org/10.1128/MCB.00289-08
   PubMed Web of Science ®Google Scholar
• Hay N. p53 strikes mTORC1 by employing sestrins. Cell Metab 2008; 3(3) 184-5; PMID:18762019; https://doi.org/10.1016/j.cmet.2008.08.010
   PubMed Web of Science ®Google Scholar
• Manfe V, Biskup E, Rosbjerg A, Kamstrup M, Guldhammer S, Lerche CM, Lauenborg BT, Odum N, Gniadecki R. miR-122 regulates p53/AKT signaling and the chemotherapy-induced apoptosis incutaneous T-cell lymphoma. PLoS One 2012; 7(1): e29541; PMID:22235305; https://doi.org/10.1371/journal.pone.0029541
   PubMed Web of Science ®Google Scholar